Keratinocyte differentiation normalization

Keratinocyte differentiation normalization is a therapeutic process and physiological outcome rather than a single molecular target or receptor. It refers to the restoration of the orderly transition of keratinocytes from the basal layer to the stratum corneum, a process that is often disrupted in hyperproliferative skin disorders like psoriasis and acne (Source: NIH/PubMed, PMID: 12133116). In these disease states, cells proliferate too rapidly and fail to mature properly, resulting in a compromised skin barrier and the accumulation of scales or follicular plugs. Therapeutic agents such as topical retinoids and vitamin D analogs induce this normalization by binding to specific nuclear receptors—Retinoic Acid Receptors (RAR) and Vitamin D Receptors (VDR), respectively—which regulate gene expression to decrease proliferation and promote the synthesis of terminal differentiation markers like filaggrin and loricrin (Source: StatPearls, 'Psoriasis'). Additionally, modern biologics targeting the IL-17/IL-23 axis indirectly promote normalization by removing inflammatory signals that inhibit proper differentiation. Because 'Keratinocyte differentiation normalization' describes a complex biological effect involving multiple signaling pathways, it is classified as a physiological endpoint rather than a discrete drug target.

Other names

Normalization of epidermal differentiationKeratinocyte maturation normalizationEpidermal differentiation

Normalization is achieved through the activation of nuclear receptors, such as Retinoic Acid Receptors (RAR) and Vitamin D Receptors (VDR), which modulate the transcription of genes responsible for keratinocyte exit from the cell cycle and the subsequent expression of structural proteins like filaggrin and involucrin (Source: StatPearls, 'Retinoids'; PubMed PMID: 27261750).